aminophylline (theophylline) ethylenediamine) (Rx)
Generic: Aminophylline
Brand: Phyllocontin
(am- in- off'i- lin)
Pharmacological Action
Exact mechanism unknown; relaxes smooth muscle of respiratory system by blocking phosphodiesterase, which increases cyclic AMP; increased cyclic AMP alters intracellular calcium ion movements; produces bronchodilatation, increased pulmonary blood flow, relaxation of respiratory tract
Therapeutic outcome: Increased ability to breathe
Uses
Apnea in infancy for respiratory/myocardial stimulation, bronchial asthma, bronchospasm associated with chronic bronchitis, emphysema Unlabeled uses: Methotrexate toxicity, sleep apnea, status asthmaticus
Contraindications
Hypersensitivity to xanthines, tachyhydrythmias
Precautions: Pregnancy C, breastfeeding, children, geriatric, CHF, cor pulmonale, hepatic disease, diabetes mellitus, hyperthyroidism, hypertension, seizure disorder, irritation of the rectum or lower colon, alcoholism, active peptic ulcer disease
Dosage & Routes
Adult: PO 6 mg/kg, then 3 mg/kg q6 hr × 2 doses, then 3 mg/kg q8 hr maintenance, max 900 mg/day or 13 mg/kg; PO in CHF 6 mg/kg, then 2 mg/kg q8 hr × 2 doses, then 1- 2 mg/kg q12 hr maintenance; IV 4.7 mg/kg, then 0.55 mg/kg/hr × 12 hr, then 0.36 mg/kg/hr maintenance; IV in CHF 4.7 mg/kg, then 0.39 mg/kg/hr × 12 hr; then 0.08- 0.16 mg/kg/hr maintenance Geriatric and in cor pulmonale: PO 6 mg/kg, then 2 mg/kg q6 hr × 2 doses, then 2 mg/kg q8 hr maintenance; IV 4.7 mg/kg, then 0.47 mg/kg/hr × 12 hr, then 0.24 mg/kg/hr maintenance Child 9- 16 yr: PO 6 mg/kg, then 3 mg/kg q4 hr × 3 doses, then 3 mg/kg q6 hr maintenance, max 18 mg/kg/day 12- 16 yr, or 20 mg/kg/day 9- 12 yr; IV 4.7 mg/kg, then 0.79 mg/kg/hr × 12 hr, then 0.63 mg/kg/hr maintenance Child 6 mo- 9 yr: PO 4 mg/kg q4 hr × 3 doses, then 4 mg/kg q6 hr maintenance, max 24 mg/kg day; IV 4.7 mg/kg, then 0.95 mg/kg/hr × 12 hr, then 0.79 mg/kg/hr maintenance Infant 6- 52 wk: Dose (0.2× age in wk) \div 5 × kg = 24 hr dose in mg Neonate up to 40 wk premature postconception age: PO/IV 1 mg/kg q12 hr Neonate at birth or 40 wk postconception age: PO/IV >8 wk postnatal 1- 3 mg/kg q6 hr; 4- 8 wk postnatal 1- 2 mg/kg q8 hr; up to 4 wk postnatal 1- 2 mg/kg q12 hr Hepatic disease
Adult: PO 6 mg/kg, then 2 mg/kg q8 hr × 2 doses, then 1- 2 mg/kg q12 hr maintenance; IV 4.7 mg/kg, then 0.39 mg/kg/hr × 12 hr, then 0.08- 0.16 mg/kg/hr maintenance
Available forms: Inj 250 mg/10 ml, 500 mg/20 ml, 100 mg/100 ml in 0.45% NaCl; 200 mg/100 ml in 0.45% NaCl; rectal supp 250 mg, 500 mg; oral liq 105 mg/5 ml; tabs 100, 200 mg; cont rel tabs 225, 350 mg
Implementation Give around the clock to maintain blood (theophylline) levels If switching from IV to PO, give controlled- release dose at time IV infusion is discontinued; if giving tab (immediate release), discontinue IV and wait >4 hr If GI upset occurs, take with 8 oz of water or food Increase fluids to 2 L/day
PO route: Do not break, crush, or chew enteric- coated or cont rel tabs Avoid giving with food
Continuous IV infusion route: May be diluted for IV inf in 100- 200 ml in D_{5}W D_{10}W D_{20}W 0.9% NaCl, 0.45% NaCl, LR Give loading dose over \frac{1}{2} hr, max rate of inf 25 mg/min, use infusion pump; after loading dose, give by cont inf Avoid IM inj; pain and tissue damage may occur Only clear sol; flush IV line before dose; store diluted sol for 24 hr if refrigerated
Syringe compatibilities: Heparin, metoclopramide, PENTobarbital, thiopental
Y- site compatibilities: Allopurinol, amifestone, amphotericin B sulfate complex, in- amrinone, aztreonam, cefTAZidine, cimetidine, cladribine, DOXOrubicin liposome, enalaprilat, esmolol, famotidine, filgrastim, fluconazole, fludarabine, foscarnet, gallium, granisetron, heparin sodium with hydrocortisone sodium succinate, labetalol, melphalan, meropenem, netilmicin, PAClitaxel, pancuronium, piperacillin/tazobactam, potassium chloride, propofol, ranitidine, remifentanil, sargramostim, tacrolimus, teniposide, thiotepa, tolazoline, vecuronium Y- site incompatibilities: DOBUTamine, hydrALAZINE, ondansetron
Adverse Effects
CNS: Anxiety, restlessness, insomnia, dizzyness, seizures, headache, light- headedness, muscle twitching, tremors
CV: Palpitations, sinus tachycardia, hypotension, flushing, dysrhythmias, edema
GI: Nausea, vomiting, diarrhea, dyspepsia, anal irritation (suppositories), epigastric pain, reflux, anorexia
GU: Urinary frequency, SIADH
INTEG: Flushing, urticaria
MISC: Hyperglycemia
RESP: Tachypnea, increased respiratory rate
Pharmacokinetics
Absorption: Well absorbed (PO), slow (PO–EXT REL), erratic (RECT)
Distribution: Widely distributed; crosses placenta
Metabolism: Liver to caffeine
Excretion: Kidneys
Half-life: 3-12 hr, increased in renal disease, CHF, geriatric patients, smokers, crosses into CSF (cerebrospinal fluid)
Pharmacodynamics
Onset: 15-60 min (PO), Unknown (PO-EXT), Immediate (IV)
Peak: 1-2 hr (PO), 4-7 hr (PO-EXT), Infusion's end (IV)
Duration: 6-8 hr (PO), 8-12 hr (PO-EXT), 6-8 hr (IV)
Interactions
Individual drugs Allopurinol (high doses), cimetidine, clarithromycin, disulfiram, erythromycin, fluvoxamine, interferon, mexiletine: decreased metabolism, increased toxicity of aminophylline CarBAMazepine, isoniazid: increased or decreased aminophylline levels
Halothane: increased risk of dysrhythmias Ketoconazole, phenytoin, rifampin: decreased aminophylline effect
Lithium: decreased effect of lithium
Smoking: increased metabolism, decreased effect
Drug classifications Barbiturates, \beta - adrenergic blockers: decreased effect of aminophylline Benzodiazepines, \beta - blockers (nonselective), corticosteroids, diuretics (loop), fluoroquinolones, influenza vaccines, oral contraceptives: increased aminophylline levels Corticosteroids, influenza vaccines: increased aminophylline toxicity Diuretics (loop): may increase or decrease aminophylline levels Dose- dependent reversal of neuromuscular blockade
Fluoroquinolones: decreased metabolism, increased toxicity
Sympathomimetics: increased CNS, CV adverse reactions
Tetracyclines: increased adverse reactions
Drug/herb Cola tree, ginseng, guarana, horsetail, Siberian ginseng, tea (black, green), yerba mate: increased effects St. John's wort: decreased effects
Drug/food High- carbohydrate, low- protein diet: decreased elimination Low- carbohydrate, high- protein diet, charcoal- broiled beef: increased elimination
Xanthines: increased effect
Drug/lab test
Increased: plasma free fatty acids
Nursing Considerations
Assessment Monitor theophylline blood levels (therapeutic level is 10 - 20 mg/ml ); toxicity may occur with small increase above 20 mg/ml , especially geriatric; determine whether theophylline was given recently (24 hr); check for toxicity: nausea, vomiting, anxiety, restlessness, insomnia, tachycardia, dysrhythmias, seizures; notify prescriber immediately Monitor I&O; diuresis will occur; dehydration may result in geriatric or children in whom diuresis is great Monitor liver function tests: periodically, lower doses may be required in those with moderate to severe hepatic disease Monitor respiratory rate, rhythm, depth; auscultate lung fields bilaterally, pulmonary function tests; notify prescriber of abnormalities; check ECG for tachycardia, PVCs, PACs in patients with cardiac problems Monitor allergic reactions: rash, urticaria; if these occur, product should be discontinued, prescriber notified
Patient/family education Teach patient to take doses as prescribed, not to skip dose; to check OTC medications, current prescription medications for ephedrine, which will increase CNS stimulation; advise patient not to drink alcohol or caffeine products (tea, coffee, chocolate, colas), which will increase action Teach patient to avoid hazardous activities; dizziness may occur Teach patient if GI upset occurs, to take product with 8 oz of water or food; absorption may be decreased Teach patient to remain in bed 15-20 min after rect supp is inserted to prevent removal Instruct patient to avoid smoking because it increases metabolism; decreases blood levels and terminal half-life; dosage may need to be increased Teach patient to obtain blood levels of product every few months to prevent toxicity; not to change brands, since effect may not be the same Teach patient to increase fluids to 2 L/day to decrease viscosity of secretions Advise patient to report toxicity: nausea, vomiting, anxiety, insomnia, rapid pulse, seizures, flushing, headache, diarrhea
Evaluation
Positive therapeutic outcome: Decreased dyspnea; Respiratory stimulation in infants; Clear lung fields bilaterally
Reference
Need clinical tools for this drug?
Save notes, bookmark this drug, and run formula method (desire over have) dosage calculations all inside the KosPharm Dashboard.
One-time payment. No subscription. No recurring charges.
Sign in to Get Full Access